Trial Profile

A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Jun 2024 According to Lundbeck media release, company announced data presentations of this trial at the 66th Annual Scientific Meeting of the American Headache Society (AHS) taking place in San Diego, Calif., June 13-16, 2024
28 Jun 2023 Results assessing clinical impact of reduced headache frequency to <4 monthly headache days (MHDs) as a treatment-related migraine prevention target goal, published in the Pain and Therapy.
27 Apr 2023 Results from PROMISE-1 and PROMISE-2 ; demonstrating the lack of a wearing off effect with eptinezumab in preventive migraine treatment, presented at the 75th Annual Meeting of the American Academy of Neurology 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com